The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously treated locally advanced or metastatic, nonsquamous non–small cell lung cancer ...
Using AI and big data, Weizmann Institute researchers build MiTEs, or natural killer/T-cell Enhancers, to combat cancers, 5 ...
Lung cancer affects many non-smokers. Learn why stigma harms patients, what truly causes lung cancer, and how compassion can ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
Joanne Cure, 78, survived stage 4 lung cancer after being given two years to live, crediting her faith, determination, and ...
Amgen's Imdelltra received full approval from the Food and Drug Administration for use in patients with lung cancer. The biotechnology company said Wednesday Imdelltra received approval for adult ...
Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US ...
The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).
FOX 5 Journalist Judayah Murray shares the inspiring story of Joanne Cure, a woman who developed advanced lung cancer despite ...
Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...
Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback